NEW ZEALAND DATA SHEET

ZOVIRAX® IV for Infusion.

Aciclovir 250 mg injection for intravenous infusion

Presentation

Freeze dried powder for Injection.

ZOVIRAX IV 250 mg: a sterile, white to off-white, freeze-dried powder in vials containing 250 mg aciclovir as the sodium salt. The sodium ion content is approximately 26 mg per vial. When reconstituted as directed ZOVIRAX IV has a pH of approximately 11.

Indications

ZOVIRAX IV for Infusion is indicated for the treatment of Herpes simplex infections.

ZOVIRAX IV for Infusion is indicated for the prophylaxis of Herpes simplex infections in immune-compromised patients.

ZOVIRAX IV for Infusion is indicated in the treatment of Varicella zoster infections.

ZOVIRAX IV for Infusion is indicated for the treatment of Herpes simplex infections in the neonate.

ZOVIRAX IV for Infusion is indicated for prophylaxis of CMV infection in bone marrow transplant recipients. It has been shown that high dose intravenous ZOVIRAX reduces the incidence and delays the onset of CMV infection. When high dose intravenous ZOVIRAX is followed by 6 months treatment with high dose oral ZOVIRAX (see prescribing information for oral ZOVIRAX) mortality and the incidence of viraemia are also reduced.

Dosage and Administration

Dosage

To be given as intravenous infusion over 1 hour.

A course of treatment with ZOVIRAX IV for Infusion usually lasts 5 days, but this may be adjusted according to the patient's condition and response to therapy. Treatment for herpes encephalitis and neonatal Herpes simplex
infections usually lasts 10 days. Treatment for neonatal herpes usually lasts 14 – 21 days.

**Dosage in adults**

Obese patients should be dosed at the recommended adult dose using ideal body weight, rather than actual body weight.

Patients with Herpes simplex (except herpes encephalitis) or Varicella zoster infections should be given ZOVIRAX IV for Infusion in doses of 5 mg/kg bodyweight every 8 hours if renal function is not impaired.

Patients with herpes encephalitis should be given ZOVIRAX IV for infusion in doses of 10 mg/kg bodyweight every eight hours provided renal function is not impaired.

Immune-compromised patients with Varicella zoster infections or patients with herpes encephalitis should be given ZOVIRAX IV for Infusion in doses of 10 mg/kg bodyweight every 8 hours provided renal function is not impaired.

For prophylaxis of CMV infection in bone marrow transplant recipients 500 mg/m^2^ ZOVIRAX should be given intravenously 3 times daily at approximately 8 hourly intervals if renal function is not impaired. The duration of treatment recommended in bone marrow transplant recipients is from 5 days before up to 30 days after transplant.

**Dosage in infants and children**

The dose of ZOVIRAX IV for Infusion for infants and children aged between 3 months and 12 years is calculated on the basis of body surface area.

Infants and children 3 months of age or older with Herpes simplex (except herpes encephalitis) or Varicella zoster infections should be given ZOVIRAX IV for Infusion in doses of 250 mg per square metre body surface area every 8 hours if renal function is not impaired.

In immune-compromised infants and children with Varicella zoster infections or children with herpes encephalitis, ZOVIRAX IV for Infusion should be given in doses of 500 mg per square metre body surface area every 8 hours if renal function is not impaired.

Limited data suggest that for the prophylaxis of CMV infection in children, over 2 years of age, who have undergone bone marrow transplantation, the adult dose may be given.

Children with impaired renal function require an appropriately modified dose, according to the degree of impairment (See Table 2 Dose adjustments in neonates, infants and children; Dosage Renal impairment).
Dosage in Neonates

The dosage of ZOVIRAX IV for Infusion in neonates is calculated on the basis of bodyweight.

The recommended regimen for treatment for known or suspected neonatal herpes is ZOVIRAX IV Infusion 20mg/kg body weight IV every 8 hours for 21 days for disseminated and CNS disease, or for 14 days for disease limited to the skin and mucous membranes. Patients with impaired renal function require an appropriately modified dose, according to the degree of impairment (see Renal impairment).

Dosage in the Elderly

The possibility of renal impairment in the elderly must be considered and the dosage should be adjusted accordingly (see Renal impairment).

Adequate hydration should be maintained.

Dosage in Renal Impairment

Caution is advised when administering ZOVIRAX IV for Infusion to patients with impaired renal function. Adequate hydration should be maintained.

The dosage of ZOVIRAX IV Infusion should be reduced in patients with impaired renal function as suggested in Table 1, Table 2, Table 3 or Table 4.

Dosage adjustment for patients with renal impairment is based on creatinine clearance, in units of mL/min for adults and adolescents and in units of mL/min/1.73m2 for infants and children less than 13 years of age.

The following adjustments in dosage are suggested.

Table 1: Dosage adjustments for ZOVIRAX IV Infusion in adults and adolescents with renal impairment for treatment of Herpes Simplex virus infections and Prophylaxis of CMV infection

<table>
<thead>
<tr>
<th>Creatinine Clearance</th>
<th>Dosage adjustments for treatment of Herpes Simplex virus infections</th>
</tr>
</thead>
<tbody>
<tr>
<td>25-50 mL/min</td>
<td>The recommended dose (5 or 10 mg/kg bodyweight) should be given every 12 hours.</td>
</tr>
<tr>
<td>10-25 mL/min</td>
<td>The recommended dose (5 or 10 mg/kg bodyweight) should be given every 24 hours.</td>
</tr>
<tr>
<td>0 (anuric)-10 mL/min</td>
<td>The recommended dose (5 or 10 mg/kg bodyweight) should be halved and administered every 24 hours.</td>
</tr>
<tr>
<td>Patients on haemodialysis</td>
<td>In patients receiving haemodialysis, the recommended dose (5 or 10 mg/kg bodyweight) should be halved and</td>
</tr>
</tbody>
</table>
administered every 24 hours and after dialysis.

<table>
<thead>
<tr>
<th>Creatinine Clearance</th>
<th>Dosage adjustments for Prophylaxis of CMV infection</th>
</tr>
</thead>
<tbody>
<tr>
<td>25-50 mL/min</td>
<td>The recommended dose (500 mg/m2) should be given every 12 hours.</td>
</tr>
<tr>
<td>10-25 mL/min</td>
<td>The recommended dose (500 mg/m2) should be given every 24 hours.</td>
</tr>
<tr>
<td>0 (anuric)-10 mL/min</td>
<td>The recommended dose (500 mg/m2) should be halved and administered every 24 hours.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patients on haemodialysis</th>
<th>Dosage adjustments for treatment of Herpes Simplex virus infections</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>In patients receiving haemodialysis, the recommended dose (500 mg/m2) should be halved and administered every 24 hours and after dialysis.</td>
</tr>
</tbody>
</table>

**Table 2:** Dosage adjustments for ZOVIRAX IV Infusion in neonates, infants and children with renal impairment for treatment of Herpes Simplex virus infections and Prophylaxis of CMV infection

<table>
<thead>
<tr>
<th>Creatinine Clearance</th>
<th>Dosage adjustments for treatment of Herpes Simplex virus infections</th>
</tr>
</thead>
<tbody>
<tr>
<td>25 to 50 ml/min/1.73 m2</td>
<td>The recommended dose (250 or 500 mg/m2 body surface area or 20 mg/kg body weight) should be given every 12 hours.</td>
</tr>
<tr>
<td>10 to 25 ml/min/1.73 m2</td>
<td>The recommended dose (250 or 500 mg/m2 body surface area or 20 mg/kg body weight) should be given every 24 hours.</td>
</tr>
<tr>
<td>0 (anuric) to 10 ml/min/1.73 m2</td>
<td>The recommended dose (250 or 500 mg/m2 body surface area or 20 mg/kg body weight) should be halved and administered every 24 hours.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patients on haemodialysis</th>
<th>Dosage adjustments for Prophylaxis of CMV infection</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>In patients receiving haemodialysis, the recommended dose (500 mg/m2) should be given every 12 hours.</td>
</tr>
</tbody>
</table>
The recommended dose (500 mg/m²) should be given every 24 hours.

The recommended dose (500 mg/m²) should be halved and administered every 24 hours.

In patients receiving haemodialysis, the recommended dose (500 mg/m²) should be halved and administered every 24 hours and after dialysis.

**Administration**

The required dose of ZOVIRAX IV for Infusion should be administered by slow intravenous infusion over a one-hour period.

ZOVIRAX IV for Infusion should be reconstituted in 10 mL of either Water for Injections BP or Sodium Chloride Injection BP (0.9% w/v) to provide a solution containing 25 mg aciclovir per mL. From the calculated dose, determine the appropriate number of vials to be used. To reconstitute each vial, add the recommended volume of infusion fluid and shake gently until the contents of the vial have dissolved completely.

After reconstitution ZOVIRAX IV for Infusion may be administered by a controlled-rate infusion pump.

Alternatively, the reconstituted solution may be further diluted to give an aciclovir concentration of not greater than 5 mg/mL (0.5%w/v) for administration by infusion:

Add the required volume of reconstituted solution to the chosen infusion solution, as recommended below, and shake well to ensure adequate mixing occurs.

For children and neonates, where it is advisable to keep the volume of infusion fluid to a minimum, it is recommended that dilution is on the basis of 4mL reconstituted solution (100 mg aciclovir) added to 20 mL of infusion fluid.

For adults, it is recommended that infusion bags containing 100mL of infusion fluid are used, even when this would give an aciclovir concentration substantially below 0.5%w/v. Thus one 100 mL infusion bag may be used for any dose between 250 mg and 500 mg aciclovir (10 and 20 mL of reconstituted solution) but a second bag must be used for doses between 500 and 1000 mg.

When diluted in accordance with the recommended schedules, ZOVIRAX IV for Infusion is known to be compatible with the following infusion fluids and stable for up to 12 hours at room temperature (15°C to 25°C).

- Sodium Chloride Intravenous Infusion BP (0.45% and 0.9%w/v);
Sodium Chloride (0.18%w/v) and Glucose (4%w/v) Intravenous Infusion BP;
Sodium Chloride (0.45%w/v) and Glucose (2.5%w/v) Intravenous Infusion BP;
Compound Sodium Lactate Intravenous Infusion BP (Hartmann's Solution).

ZOVIRAX IV for Infusion when diluted in accordance with the above schedule will give an aciclovir concentration not greater than 0.5%w/v.

Since no antimicrobial preservative is included, reconstitution and dilution must be carried out under full aseptic conditions, immediately before use, and any unused solution discarded.

Should any visible turbidity or crystallisation appear in the solution before or during infusion, the preparation should be discarded.

Contraindications

ZOVIRAX IV for Infusion is contraindicated in patients known to be hypersensitive to aciclovir or valaciclovir.

Warnings and Precautions

Use in patients with renal impairment and in elderly patients

ZOVIRAX IV is eliminated by renal clearance, therefore the dose must be reduced in patients with renal impairment (see Dosage and Administration). Elderly patients are likely to have reduced renal function and therefore the need for dose reduction must be considered in this group of patients. Both elderly patients and patients with renal impairment are at increased risk of developing neurological side effects and should be closely monitored for evidence of these effects. In the reported cases, these reactions were generally reversible on discontinuation of treatment (see Adverse Effects).

In patients receiving ZOVIRAX IV for Infusion at higher doses (e.g. for herpes encephalitis), specific care regarding renal function should be taken, particularly when patients are dehydrated or have any renal impairment.

Reconstituted ZOVIRAX IV for Infusion has a pH of approximately 11.0 and should not be administered by mouth.

Use in pregnancy

A post-marketing aciclovir pregnancy registry has documented pregnancy outcomes in women exposed to any formulation of ZOVIRAX. The registry findings have not shown any increase in the number of birth defects amongst ZOVIRAX exposed subjects compared with the general population, and any birth defects showed no uniqueness or consistent pattern to suggest a common cause.
The use of ZOVIRAX Powder for IV Infusion should be considered only when the potential benefits outweigh the possibility of unknown risks.

**Teratogenicity**

Systemic administration of aciclovir in internationally accepted standard tests did not produce embryotoxic or teratogenic effects in rabbits, rats or mice.

In a non-standard test in rats, foetal abnormalities were observed but only following such high subcutaneous doses that maternal toxicity was produced. The clinical relevance of these findings is uncertain.

**Use in lactation**

Following oral administration of 200 mg aciclovir five times a day, aciclovir has been detected in human breast milk at concentrations ranging from 0.6 to 4.1 times the corresponding plasma levels. These levels would potentially expose nursing infants to aciclovir dosages of up to 0.3 mg/kg bodyweight/day. Caution is therefore advised if ZOVIRAX is to be administered to a nursing woman.

**Effects on ability to drive and use machines**

ZOVIRAX IV for Infusion is generally used in an in-patient hospital population and information on ability to drive and operate machinery is not usually relevant. There have been no studies to investigate the effect of ZOVIRAX on driving performance or the ability to operate machinery.

**Adverse Effects**

The frequency categories associated with the adverse events below are estimates. For most events, suitable data for estimating incidence were not available. In addition, adverse events may vary in their incidence depending on the indication.

The following convention has been used for the classification of undesirable effects in terms of frequency:

Very common (>1/10); common (>1/100 to <1/10), uncommon (>1/1000 to <1/100); rare (>1/10,000 to <1/1000); very rare (<1/10,000).

**Blood and lymphatic system disorders**

Uncommon: Decreases in haematological indices (anaemia, thrombocytopenia, leukopenia)

**Immune system disorders**

Very rare: Anaphylaxis

**Psychiatric and nervous system disorders**
Very rare: Headache, dizziness, agitation, confusion, tremor, ataxia, dysarthria, hallucinations, psychotic symptoms, convulsions, somnolence, encephalopathy, coma

The above events are generally reversible and usually reported in patients with renal impairment or with other predisposing factors (see Warnings and Precautions).

**Vascular disorders**  
Common: Phlebitis

**Respiratory, thoracic and mediastinal disorders**  
Very rare: Dyspnoea

**Gastrointestinal disorders**  
Common: Nausea, vomiting  
Very rare: Diarrhoea, abdominal pain

**Hepato-biliary disorders**  
Common: Reversible increases in liver-related enzymes  
Very rare: Reversible increases in bilirubin, jaundice, hepatitis

**Skin and subcutaneous tissue disorders**  
Common: Pruritus, urticaria, rashes (including photosensitivity)  
Very rare: Angioedema

**Renal and urinary disorders**  
Common: Increases in blood urea and creatinine  
Rapid increases in blood urea and creatinine levels are believed to be related to the peak plasma levels and the state of hydration of the patient. To avoid this effect, when administered intravenously the drug should not be given as an intravenous bolus injection but by slow infusion over a one-hour period.  
Very rare: Renal impairment, acute renal failure, renal pain  
Adequate hydration should be maintained. Renal impairment usually responds rapidly to rehydration of the patient and/or dosage reduction or withdrawal of the drug. Progression to acute renal failure, however, can occur in exceptional cases. Renal pain may be associated with renal failure

**General disorders and administration site conditions**  
Very rare: Fatigue, fever, local inflammatory reactions
Severe local inflammatory reactions sometimes leading to breakdown of the skin have occurred when ZOVIRAX IV for Infusion has been inadvertently infused into extracellular tissues.

Interactions

No clinically significant interactions have been identified.

Aciclovir is eliminated primarily unchanged in the urine via active renal tubular secretion. Any drugs administered concurrently that compete with this mechanism may increase aciclovir plasma concentrations. Probenecid and cimetidine increase the AUC of aciclovir by this mechanism, and reduce aciclovir renal clearance. However no dosage adjustment is necessary because of the wide therapeutic index of aciclovir.

In patients receiving intravenous ZOVIRAX, caution is required during concurrent administration with drugs which compete with aciclovir for elimination, because of the potential for increased plasma levels of one or both drugs or their metabolites. Increases in plasma AUCs of aciclovir and of the inactive metabolite of mycophenolate mofetil, an immunosuppressant agent used in transplant patients, have been shown when the drugs are coadministered.

Care is also required (with monitoring for changes in renal function) if administering intravenous ZOVIRAX with drugs which affect other aspects of renal physiology (e.g. cyclosporin, tacrolimus).

Overdosage

Overdosage of intravenous aciclovir has resulted in elevations of serum creatinine, blood urea nitrogen and subsequent renal failure. Neurological effects including confusion, hallucinations, agitation, seizures and coma have been described in association with overdosage. Patients should be observed closely for signs of toxicity. Haemodialysis significantly enhances the removal of aciclovir from the blood and may, therefore, be considered a management option in the event of symptomatic overdose of this drug.

Pharmaceutical Precautions

Shelf Life

60 months. Store below 25°C.

Special precautions for storage

Reconstituted or diluted solutions should not be refrigerated.
**Nature and contents of container**

Pack of 5 vials.

**Instructions for use/handling**

ZOVIRAX IV for Infusion contains no antimicrobial preservative.

Reconstitution or dilution should therefore be carried out either under full aseptic conditions or immediately before use and any unused solution discarded.

When reconstituted as directed, ZOVIRAX IV for Infusion has a pH of approximately 11.

Reconstituted or diluted solutions should not be refrigerated.

**Reconstitution**

ZOVIRAX IV for Infusion should be reconstituted using 10 mL of either Water for Injections BP or Sodium Chloride Injection BP (0.9% w/v) to provide a solution containing 25 mg aciclovir per mL (see Dosage and Administration).

---

**Medicines Schedule**

Prescription Only Medicine

---

**Further Information**

**Actions**

**Mechanism of Action**

Aciclovir is a synthetic purine nucleoside analogue with *in vitro* and *in vivo* inhibitory activity against human herpes viruses, including Herpes simplex virus types 1 and 2, Varicella zoster virus (VZV), Epstein Barr virus (EBV) and Cytomegalovirus (CMV). In cell culture, aciclovir has the greatest antiviral activity against HSV-1, followed (in decreasing order of potency) by HSV-2, VZV, EBV and CMV.

The inhibitory activity of aciclovir for HSV-1, HSV-2, VZV and EBV is highly selective. The enzyme thymidine kinase (TK) of normal, uninfected cells does not use aciclovir effectively as a substrate, hence toxicity to mammalian host cells is low; however, TK encoded by HSV, VZV and EBV converts aciclovir to aciclovir monophosphate, a nucleoside analogue, which is further converted to the diphosphate and finally to the triphosphate by cellular enzymes. Aciclovir triphosphate interferes with the viral DNA polymerase and inhibits
viral DNA replication with resultant chain termination following its incorporation into the viral DNA.

**Pharmacodynamics**

Prolonged or repeated courses of aciclovir in severely immune-compromised individuals may result in the selection of virus strains with reduced sensitivity, which may not respond to continued aciclovir treatment. Most of the clinical isolates with reduced sensitivity have been relatively deficient in viral TK; however, strains with altered viral TK or viral DNA polymerase have also been reported. *In-vitro* exposure of HSV isolates to aciclovir can also lead to the emergence of less sensitive strains. The relationship between the *in vitro* determined sensitivity of HSV isolates and clinical response to aciclovir therapy is not clear. All patients should be cautioned to ensure they avoid the potential of virus transmission, particularly when active lesions are present.

**Pharmacokinetics**

In adults the terminal plasma half life of aciclovir after administration of ZOVIRAX IV for Infusion is about 2.9 hours. Most of the drug is excreted unchanged by the kidney. Renal clearance of aciclovir is substantially greater than creatinine clearance indicating that tubular secretion in addition to glomerular filtration contributes to the renal elimination of the drug. 9-carboxymethoxy-methylguanine is the only significant metabolite of aciclovir and accounts for approximately 10-15% of the dose excreted in the urine. When aciclovir is given one hour after 1 gram of probenecid the terminal half life and the area under the plasma concentration time curve is extended by 18% and 40% respectively.

In adults, mean steady state peak plasma concentrations (Cssmax) following a one-hour infusion of 2.5 mg/kg, 5 mg/kg, 10 mg/kg and 15 mg/kg were 22.7 mcM (5.1 mcg/mL), 43.6mcM (9.8 mcg/mL), 92 mcM (20.7 mcg/mL) and 105 mcM (23.6 mcg/mL), respectively. The corresponding trough levels (Cssmin) 7 hours later were 2.2 mcM (0.5 mcg/mL), 3.1mcM (0.7 mcg/mL), 10.2 mcM (2.3 mcg/mL) and 8.8 mcM (2.0 mcg/mL), respectively. In children over 1 year of age similar mean peak (Cssmax) and trough (Cssmin) levels were observed when a dose of 250 mg/m^2^ was substituted for 5 mg/kg and a dose of 500 mg/m^2^ was substituted for 10 mg/kg. In neonates (0-3 months of age) treated with doses of 10 mg/kg administered by infusion over a one-hour period every 8 hours the Cssmax was found to be 61.2 mcM (13.8 mcg/mL) and the Cssmin to be 10.1 mcM (2.3 mcg/mL). A separate group of neonates treated with 15 mg/kg every 8 hours showed approximate dose proportional increases, with a Cmax of 83.5 micromolar (18.8 micrograms/mL) and Cmin of 14.1 micromolar (3.2 micrograms/mL).

The terminal plasma half life in these patients was 3.8 hours. In the elderly total body clearance falls with increasing age, associated with decreases in creatinine clearance, although there is little change in the terminal plasma half life.
In patients with chronic renal failure the mean terminal half life was found to be 19.5 hours. The mean aciclovir half life during haemodialysis was 5.7 hours. Plasma aciclovir levels dropped approximately 60% during dialysis.

Cerebrospinal fluid levels are approximately 50% of corresponding plasma levels. Plasma protein binding is relatively low (9 to 33%) and drug interactions involving binding site displacement are not anticipated.

**Preclinical Safety Data**

**Mutagenicity**

The results of a wide range of mutagenicity tests *in vitro* and *in vivo* indicate that aciclovir is unlikely to pose a genetic risk to man.

Carcinogenicity:
Aciclovir was not found to be carcinogenic in long-term studies in the rat and the mouse.

**Fertility**

Largely reversible adverse effects on spermatogenesis in association with overall toxicity in rats and dogs have been reported only at doses of aciclovir greatly in excess of those employed therapeutically. Two-generation studies in mice did not reveal any effect of (orally administered) aciclovir on fertility.

There is no information on the effect of ZOVIRAX IV for Infusion on human female fertility. In a study of 20 male patients with normal sperm count, oral aciclovir administered at doses of up to 1 g per day for up to six months has been shown to have no clinically significant effect on sperm count, motility or morphology.

**Excipients**

ZOVIRAX IV for Infusion contains sodium hydroxide.

---

**Name and Address**

GlaxoSmithKline NZ Limited  
Private Bag 106600  
Downtown Auckland  
NEW ZEALAND

Phone: (09) 367 2900  
Fax: (09) 367 2506

**Date of Preparation**

12